Rob Wright highlights the “integrative thinking” work of Jennifer Riel and Roger Martin, professors at the Rotman School of Management, University of Toronto, in helping leaders make great choices, drawing on LEGO’s entry into feature films as an example.

There are three things you should never talk about in polite company: religion, politics, and money. Still, I’d like to briefly discuss two of those — bear with me. 

Biopharmaceutical executives Ron Cohen, Acorda Therapeutics; John Maraganore, Alnylam; and Helen Torley, Halozyme Therapeutics, discuss BIO’s approach toward increasing diversity among the industry’s leadership.

Xencor’s story seems riddled with more than your average share of challenges, hurdles, and outright roadblocks. But it’s the outcome of that story — a growing company now valued at roughly $1.8 billion with nine drugs in the clinic and 150 employees — that truly make’s Xencor’s journey so compelling.

Chris Anselmo provides his thoughts as a first time panelist and attendee of the 2019 BIO International Convention and Conference, Philadelphia, PA, June 3 - 6.

While the annual BIO International Convention and Conference has much in common with the annual J.P. Morgan Healthcare Conference, first time attendee of BIO, Matt Pillar, quickly picks up on key points of differentiation at BIO 2019 this year in Philadelphia, PA, June 3 - 6.

So, why should pharma care about digital therapeutics? This was just one of the questions posed to a panel of digital therapeutics experts during the 2018 CNS Summit.

Whether it’s product promotion or pricing practices, biopharma’s inability to envision long-term consequences when implementing short-term decisions further handicaps what it is trying to do.

Rob Wright provides insight into the categories and shared attributes of superbosses, as derived from 10 years of research and more than 200 interviews by Sydney Finkelstein, #23 on the Thinker50 2017 rankings.